

# Biotech Capital.

Biotech Capital (BTC) -ASX Announcement

27 February 2017

## APPOINTMENT OF SENIOR BUSINESS DEVELOPMENT EXECUTIVE

Biotech Capital Limited (ASX:BTC) announced today that it has appointed Dr. Rocco Iannello as Group Business Development Director in its Melbourne office, to lead the marketing of the group's services and capabilities to a growing number of local and international clients.

Rocco has a Ph.D. from the University of Sydney and a MBA from Monash University. He has over 25 years experience in biomedical research, business development, technology commercialisation and industry/government engagement. Between 2002 and 2015 he held senior executive business development positions at Monash Commercial and Monash Institute of Pharmaceutical Sciences. He has held directorships with a number of industry organisations and biotech start-up companies and brings to the role an extensive global network in the biotech and pharmaceutical industries.

Through its Biointelect and Bio101 subsidiaries, Biotech Capital provides high-quality professional services including market evaluations, product development and commercialisation strategies, along with fully integrated company finance, tax and administration services. The group is currently in the process of expanding its regulatory, clinical and quality capabilities.

Biotech Capital's Chairman Dr. Richard Treagus commented; "We are very fortunate to have an individual of Rocco's calibre join our team and given his wealth of commercialisation experience and industry network we expect that the BTC group will continue to build on our working relationships with the venture capital firms, research institutes and university commercialisation offices."

### About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and add value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

# Biotech Capital.

## *Forward-looking Statements*

*This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.*

## **For more information, please contact:**

Dr. Richard Treagus, Executive Chairman

[rtreagus@biotechcapital.com.au](mailto:rtreagus@biotechcapital.com.au)

+61 417 520509